Cypherpunk Technologies (CYPH) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Special Meeting scheduled for December 15, 2025, to vote on five key proposals impacting capital structure, governance, and compensation.
$58.88 million private placement completed in October 2025, led by Winklevoss Capital, to support digital asset treasury strategy and therapeutic development.
Board unanimously recommends voting in favor of all proposals to enhance financial flexibility and maintain Nasdaq listing.
Voting matters and shareholder proposals
Proposal 1: Amend charter to increase authorized shares from 250M to 500M, with 490M as common stock.
Proposal 2: Authorize Board to effect a reverse stock split (1:5 to 1:20) within one year to regain Nasdaq compliance.
Proposal 3: Approve 2025 Equity Incentive Plan, authorizing up to 31.45M shares for grants, with an evergreen provision.
Proposal 4: Approve issuance of up to 152.75M shares upon warrant exercise from the private placement, potentially triggering a change of control under Nasdaq rules.
Proposal 5: Authorize adjournment of the meeting if more votes are needed for any proposal.
Board of directors and corporate governance
Winklevoss Capital, as Lead Investor, gains right to nominate up to two directors, including the Board chair, based on ownership thresholds.
Board expanded to twelve members post-financing; Board supports all proposals.
Non-employee directors receive annual cash retainers and stock option grants; Lead Independent Director receives additional compensation.
Latest events from Cypherpunk Technologies
- Returned to profitability in 2025 with strong ZEC gains, new capital, and clinical progress.CYPH
Q4 202516 Mar 2026 - Phase 2 trials for DKN-01 in gastric and colorectal cancer near key data readouts and expansion.CYPH
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Sirexatamab shows strong efficacy in GI cancer trials; FL-501 advances toward clinical studies.CYPH
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - Sirexatamab improved response rates in CRC, especially in DKK1-high and VEGF-naive patients.CYPH
Study Result9 Jan 2026 - Shareholders approved key proposals including share increase, reverse split, and new equity plan.CYPH
AGM 202515 Dec 2025 - Virtual meeting to elect directors, approve pay, and ratify auditor, with strong governance.CYPH
Proxy Filing2 Dec 2025 - Stockholders will vote on key capital structure changes and equity plans at a virtual meeting.CYPH
Proxy Filing2 Dec 2025 - Virtual annual meeting on June 18, 2025, with key votes on directors, pay, and auditor.CYPH
Proxy Filing2 Dec 2025 - Sirexatamab delivers higher response rates and PFS in key colorectal cancer subgroups.CYPH
Status Update24 Nov 2025